Site #185 — Omaha, Nebraska

Site #185 is a clinical research site located in Omaha, Nebraska, United States 68114.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

Site #185 has participated in 1 clinical trials.

Therapeutic areas: Metastatic Pancreatic Ductal Adenocarcinoma.

Sponsors: Corcept Therapeutics.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Omaha

Browse all research sites in Nebraska · View every site in Omaha

• Methodist Cancer Center at Methodist Hospital - Omaha
• Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha
• University of Nebraska Medical Center, College of Nursing
• Nebraska Medical Hospital
• University of Nebraska Medical Center, Lauritzen Outpatient Center
• Creighton University Psychiatry Research Center
• VA Medical Center, Omaha
• Marc Rendell, MD - Creighton University
• The Cardiac Center of Creighton University
• Methodist Hospital Cancer Center - Omaha
• University of Nebraska /ID# 203195
• Eppley Cancer Center, University of Nebraska Medical Center

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site #185?

Site #185 has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site #185 conducted?

Site #185 has 1 clinical trials on record. Their work covers Metastatic Pancreatic Ductal Adenocarcinoma.

Is Site #185 accredited by Crixeo Clinical Trials?

Site #185 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site #185?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.